Latest period
$4.99M
YoY change
-100.0%
5Y CAGR
-100.0%
Peak year (2023)
$12.81M
Latest annual
$0.00
Stock-Based Compensation history chart for Climb Bio (CLYM) from 2019 to 2025
Latest: $0.00
Stock-Based Compensation growth chart for Climb Bio (CLYM) from 2019 to 2025
Latest: -100.0%
Stock-Based Compensation history table for Climb Bio (CLYM) from 2019 to 2025
| 2025 | $0.00 | -100.0% | −$5.56M | ||
| 2024 | $5.56M | -56.6% | −$7.25M | ||
| 2023 | $12.81M | +83.2% | +$5.82M | ||
| 2022 | $6.99M | +87.1% | +$3.25M | ||
| 2021 | $3.74M | +428.6% | +$3.03M | ||
| 2020 | $707.00K | — | +$707.00K | ||
| 2019 | $0.00 | — | — |
- 2025$0.00-100.0%
- 2024$5.56M-56.6%
- 2023$12.81M+83.2%
- 2022$6.99M+87.1%
- 2021$3.74M+428.6%
- 2020$707.00K—
- 2019$0.00—
Stock-Based Compensation values are taken from Climb Bio's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Climb Bio (CLYM)
Stock-Based Compensation for Climb Bio (CLYM): headline value $4.99M · YoY -100.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Climb Bio (CLYM) reported stock-based compensation of $0.00 – plunged 100.0% year-over-year.
Through 2020–2025 (5 years), Climb Bio stock-based compensation delivered a -100.0% annualised rate; with a net decline across the window.
The record annual stock-based compensation stands at $12.81M, reached in 2023; the historical low of $0.00 was recorded in 2019.
Climb Bio Stock-Based Compensation by Year
Climb Bio Stock-Based Compensation 2025: $0.00
2025's stock-based compensation for Climb Bio came in at $0.00, plunged 100.0% below 2024.
Climb Bio Stock-Based Compensation 2024: $5.56M
Climb Bio posted stock-based compensation of $5.56M in 2024, plunged 56.6% below 2023.
Climb Bio Stock-Based Compensation 2023: $12.81M
In 2023, Climb Bio reported stock-based compensation of $12.81M, surged 83.2% from 2022. This figure represents the highest annual value in the available history.
Climb Bio Stock-Based Compensation 2022: $6.99M
Climb Bio stock-based compensation in 2022 was $6.99M, surged 87.1% from 2021.
Climb Bio Stock-Based Compensation 2021: $3.74M
Climb Bio stock-based compensation in 2021 was $3.74M.
See more financial history for Climb Bio (CLYM).
Sector peers by Stock-Based Compensation
Healthcare peers of Climb Bio (CLYM), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Climb Bio (CLYM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation